Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
Farmers Insurance
Cerilliant
UBS
Argus Health
Chinese Patent Office
Dow
Moodys

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021087

« Back to Dashboard

NDA 021087 describes TAMIFLU, which is a drug marketed by Roche and is included in two NDAs. It is available from five suppliers. Additional details are available on the TAMIFLU profile page.

The generic ingredient in TAMIFLU is oseltamivir phosphate. There are seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the oseltamivir phosphate profile page.
Summary for 021087
Tradename:TAMIFLU
Applicant:Roche
Ingredient:oseltamivir phosphate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 021087
Mechanism of ActionNeuraminidase Inhibitors
Medical Subject Heading (MeSH) Categories for 021087
Suppliers and Packaging for NDA: 021087
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087 NDA Genentech, Inc. 0004-0800 0004-0800-07 1 BOTTLE, PLASTIC in 1 CARTON (0004-0800-07) > 10 CAPSULE in 1 BOTTLE, PLASTIC
TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087 NDA Genentech, Inc. 0004-0800 0004-0800-08 1 BOTTLE, PLASTIC in 1 CARTON (0004-0800-08) > 10 CAPSULE in 1 BOTTLE, PLASTIC

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 75MG BASE
Approval Date:Oct 27, 1999TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 2, 2007TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 30MG BASE
Approval Date:Jul 2, 2007TE:ABRLD:Yes

Expired US Patents for NDA 021087

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-001 Oct 27, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-002 Jul 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Roche TAMIFLU oseltamivir phosphate CAPSULE;ORAL 021087-003 Jul 2, 2007 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Baxter
Dow
UBS
Harvard Business School
Chinese Patent Office
Fish and Richardson
Express Scripts
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.